News

09/16/21	Coherus and Junshi Biosciences to Present Positive Progression Free Survival and Overall Survival Results from JUPITER-06, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma - Interim results to be presented September 17 at the European Society for Medical Oncology (ESMO) Congress 2021 - - Data support the use of toripalimab with chemotherapy as first-line therapy for patients with ESCC – - Coherus and Junshi Biosciences plan to submit a BLA supplement for 1L ESCC in
09/15/21	Coherus and Junshi Biosciences Announce Results from Phase 3 Study of Toripalimab Published in September Issue of Nature Medicine - Toripalimab plus standard chemotherapy demonstrates improvement in PFS in first-line advanced nasopharyngeal carcinoma - REDWOOD CITY, Calif. , and SHANGHAI, China , Sept. 15, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd
09/13/21	Positive Interim Results of CHOICE-01 Study Evaluating Coherus' and Junshi Biosciences’ Toripalimab for First Line Treatment of Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer REDWOOD CITY, Calif. and SHANGHAI, China , Sept. 13, 2021 (GLOBE NEWSWIRE) -- Coherus Biosciences, Inc. (Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) announced the presentation today of positive interim results from the pivotal study
09/10/21	Coherus Management to Present at the H.C. Wainwright 23rd Annual Global Investment Conference REDWOOD CITY, Calif. , Sept. 10, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences , Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the 23 rd Annual H.C. Wainwright Global Investment Conference . The presentation will be made available at 7 a.m.
09/08/21	Coherus BioSciences Announces Upcoming Medical Conference Presentations REDWOOD CITY, Calif. , Sept. 08, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences , Inc. (“Coherus”, Nasdaq: CHRS), today announced upcoming medical conference presentations. Toripalimab clinical data will be presented September 13 at the IASLC 2021 World Conference on Lung Cancer and September 17 at
09/01/21	Coherus and Junshi Biosciences Announce Completion of Rolling BLA Submission to U.S. FDA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma SHANGHAI, China , and REDWOOD CITY, Calif. , Sept. 01, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus Biosciences, Inc. (“Coherus”, Nasdaq: CHRS) announced today the completion of the rolling submission of the Biologics
08/27/21	Coherus BioSciences Announces New Employment Inducement Grants REDWOOD CITY, Calif. , Aug. 27, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective Aug. 26, 2021 , the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 278,000 shares of
08/18/21	Coherus and Junshi Biosciences Announce Positive Interim Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer – Toripalimab plus chemotherapy met primary endpoint with significant improvement in PFS compared to chemotherapy alone – - Data support the use of toripalimab with chemotherapy as first-line therapy for patients with NSCLC - - Study to be presented September 13 at IASLC 2021 World Conference on
08/12/21	Junshi Biosciences and Coherus Announce U.S. FDA Breakthrough Therapy Designation Granted for Toripalimab for 1st Line Treatment of Nasopharyngeal Carcinoma –1st line nasopharyngeal indication and 2nd/3rd line indications to be concurrently submitted 3Q 2021 in the toripalimab BLA– SHANGHAI, China , and REDWOOD CITY, Calif. , Aug. 12, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and
08/05/21	Coherus BioSciences Reports Second Quarter 2021 Financial Results and Immuno-oncology and Biosimilar Pipeline Progress –1 st line nasopharyngeal indication and 2 nd /3 rd line indications to be concurrently submitted 3Q 2021 in the toripalimab BLA — – CHS-201 (Lucentis® biosimilar) BLA submitted to FDA – –CHS-1420 (Humira® biosimilar) BLA review progressing with December target action date – – Second quarter 2021
07/26/21	Coherus BioSciences to Report Second Quarter 2021 Financial Results on August 5th REDWOOD CITY, Calif. , July 26, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its second quarter 2021 financial results will be released after market close on Thursday, August 5, 2021 . Starting at 5 p.m.
07/21/21	Coherus BioSciences Names Physician-Scientist Ildiko Csiki, M.D., Ph.D., Chair of its Scientific Advisory Board - Csiki has over two decades of experience in research and drug development of cancer immunotherapies - REDWOOD CITY, Calif. , July 21, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced the appointment of Ildiko Csiki , M.D., Ph.D., a leader in the field
07/12/21	Coherus BioSciences Announces New Employment Inducement Grants REDWOOD CITY, Calif. , July 12, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective July 6, 2021 , the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 221,500 shares of
06/04/21	Coherus and Junshi Biosciences to Host Virtual Investor Event to Discuss Toripalimab and ASCO 2021 Highlights – Virtual investor event to take place on Monday, June 7, 2021 at 6 p.m. ET – SHANGHAI, China , and REDWOOD CITY, Calif. , June 04, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co. , Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc.
06/03/21	Coherus and Junshi Biosciences Announce Toripalimab in Combination with Chemotherapy Met Primary Progression Free Survival (PFS) Endpoint as First Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) – In pivotal Phase 3 JUPITER-02 study, toripalimab plus chemotherapy significantly improved PFS compared to chemotherapy alone in high and low PD-L1 expression subgroups – – Although median overall survival (OS) analysis was not yet mature, a 40% reduction in risk of death was observed in the
05/07/21	Coherus BioSciences to Present at the Bank of America Health Care Conference REDWOOD CITY, Calif. , May 07, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the upcoming Bank of America Health Care Conference on Wednesday, May 12, 2021 at 1:15 p.m. EST / 10:15 a.m. PST .
05/06/21	Coherus BioSciences Reports First Quarter 2021 Financial Results and Immuno-oncology and Biosimilar Pipeline Progress – Junshi Biosciences transaction is followed by rapid toripalimab progress including initiation of first BLA submission to the U.S. FDA, positive interim analysis in pivotal esophageal cancer trial, and selection for ASCO plenary session – –Toripalimab is one of four additional Coherus product
04/30/21	Coherus BioSciences Announces New Employment Inducement Grants REDWOOD CITY, Calif. , April 30, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective April 28, 2021 , the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 483,000 shares
04/30/21	Coherus BioSciences to Report First Quarter 2021 Financial Results on May 6th REDWOOD CITY, Calif. , April 30, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that its first quarter 2021 financial results will be released after market close on Thursday, May 6, 2021 . Starting at 4:30 p.m.
04/29/21	Junshi Biosciences and Coherus Announce Toripalimab First-Line Nasopharyngeal Carcinoma Clinical Data to be Showcased in Plenary Session at 2021 ASCO Annual Meeting - Toripalimab data will also be featured in ASCO’s official press program - SHANGHAI, China , and REDWOOD CITY, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co. , Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq:
04/23/21	Coherus Announces Toripalimab Achieved Primary Endpoints of Progression Free Survival and Overall Survival in Interim Analysis of Phase 3 Clinical Trial in First-Line Esophageal Squamous Cell Carcinoma REDWOOD CITY, Calif. , April 23, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS) has received notice from immuno-oncology partner Junshi Biosciences that the Independent Data Monitoring Committee of the JUPITER-06 clinical trial has determined that toripalimab, an anti-PD-1
04/20/21	Coherus Announces Closing of Sale of Common Stock to Immuno-Oncology Partner Junshi Biosciences Coherus received $50 million from sale of 2,491,998 shares at $20.06 per share REDWOOD CITY, Calif. , April 20, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences , Inc. (“Coherus”, Nasdaq: CHRS), today announced the closing of the sale of Coherus common stock to Junshi Biosciences.
03/03/21	Junshi Biosciences and Coherus BioSciences Announce Initiation of Rolling Submission of BLA for Toripalimab to the U.S. FDA for the Treatment of Nasopharyngeal Carcinoma - BLA submitted with FDA’s breakthrough therapy designation – SHANGHAI, China , and REDWOOD CITY, Calif. , March 03, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus Biosciences, Inc.
02/25/21	Coherus Management to Present at Upcoming Investor Conferences REDWOOD CITY, Calif. , Feb. 25, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), announced today that senior management will present at the following investor conferences in March. 41 st Annual Cowen Healthcare Conference on Monday, March 1 at 4 p.m.
02/24/21	Coherus BioSciences Reports Fourth Quarter and Full Year 2020 Financial Results - Product revenues of $476 million for full year 2020, $110 million for the fourth quarter of 2020 - - Expanding late-stage opportunities with Junshi Biosciences immuno-oncology collaboration with first BLA filing expected this year - - Pipeline progress with CHS-1420 (adalimumab biosimilar) BLA
02/18/21	Coherus BioSciences to Report Fourth Quarter and Full Year 2020 Financial Results on February 24th REDWOOD CITY, Calif. , Feb. 18, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that it will release fourth quarter and full year 2020 financial results after the market closes on Wednesday, February 24, 2021.
02/17/21	Coherus BLA Filing for Adalimumab Biosimilar Candidate Accepted by FDA for Review REDWOOD CITY, Calif. , Feb. 17, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) announced that the United States Food and Drug Administration (“FDA”) has accepted for review the 351(k) Biologics License Application (“BLA”) for CHS-1420, a Humira®
02/16/21	Coherus Announces CFO Transition Plans REDWOOD CITY, Calif. , Feb. 16, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) announced that Chief Financial Officer Jean-Frédéric Viret, Ph.D. will resign from Coherus effective March 7, 2021 to pursue another opportunity.
02/02/21	Coherus BioSciences to Receive $50 million Strategic Investment from Immuno-Oncology Partner Junshi Biosciences REDWOOD CITY, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) -- A day after announcing their new immuno-oncology collaboration, Coherus BioSciences, Inc. (Nasdaq: CHRS) (“Coherus”) announced that Shanghai Junshi Biosciences Co., Ltd (HK: 1877; SH: 688180) (“Junshi Biosciences”) intends to make a strategic
02/01/21	Coherus BioSciences to expand late-stage pipeline to immuno-oncology with in-license of Junshi Biosciences’ PD-1, toripalimab, in United States and Canada - Coherus to pay $150 million upfront for U.S. and Canada rights to toripalimab, an extensively studied, late-stage anti-PD-1 antibody - First U.S. BLA filing expected this year for nasopharyngeal carcinoma with breakthrough therapy designation - Options to PD-1 combination agents, TIGIT and IL-2,
01/22/21	Coherus BioSciences Announces New Employment Inducement Grants REDWOOD CITY, Calif. , Jan. 22, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective January 21, 2021 , the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 60,000 shares
01/07/21	Coherus BioSciences Appoints Alan Mendelson and Mark Stolper to Board of Directors REDWOOD CITY, Calif. , Jan. 07, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced the appointments of Alan C. Mendelson and Mark D. Stolper to its Board of Directors effective January 5, 2021 . “We are excited to welcome Alan and Mark to the Coherus
01/05/21	Coherus BioSciences Management to Present at the 39th Annual J.P. Morgan Healthcare Conference REDWOOD CITY, Calif. , Jan. 05, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the virtual 39 th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 10:50 a.m. EST / 7:50 a.m. PST .